ClinicalTrials.gg
Status unknownNCT03494088Updated May 14, 2018

Mycobiome Evaluation in Children With Autism & GI Symptoms

An observational study in Autism and Gastrointenstinal Symptoms, sponsored by The University of Texas Health Science Center, Houston. Status unknown at 1 site in United States. Open to participants aged 4 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-14.

Sponsored by The University of Texas Health Science Center, Houston · Observational

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Planned enrollment
67th of 96
60 · median 135
Started
2018
with 16 others
Observational
96 of 603
15 open now
Registered
345th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 67th largest by planned enrollment of the 96 observational ones that give a count, is one of 17 that started in 2018, is one of 96 observational ones, and was the 345th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

This study's primary aim is to explore the potential differences in the gut mycobiome of children with autism spectrum disorder compared to otherwise healthy children. The secondary objective of this study is to evaluate whether the presence of specific species of fungi (e.g. Candida tropicalis, C. albicans, or Saccharomyces cerevisiae), in stool: 1) correlates with increased gastrointestinal symptoms; 2) correlates with evidence of increased behavioral problems (as assessed by the Aberrant Behavior Checklist or Social Responsiveness Scale-2); or 3) plays the same role as a constituent of commensal gut microflora as in normal controls. The scale indicates severity of social deficits in the autism spectrum as mild, moderate or severe. Additionally, the study aims to compare the fecal and oral fungi in these children because many fecal mycobiota are felt to originate in the oropharynx.

03

Conditions studied

  • Autism
  • Gastrointenstinal Symptoms

Keywords

  • Autism
  • Abdominal Pain
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy subjects will be recruited from The University of Texas Health Science Center at Houston general pediatrics clinic and adolescent clinic.

Children with autism are referred to The University of Texas Health Science Center at Houston general pediatrics clinic and adolescent clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for autistic children with GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2); substantial gastrointestinal symptoms (as indicated by score of greater than 7 on the Gastrointestinal Symptoms Severity Index)
  • for autistic children without GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (DSM-5: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2)
  • for controls: healthy children

Exclusion criteria

Exclusion Criteria:

  • severe sensory impairment
  • brain injury
  • major psychiatric illness (e.g., psychotic disorders that might interfere with assessment). (however, children with common psychological problems such as depression and attention deficit hyperactivity disorder will not be excluded, given that doing so would result in a sample of children with ASD that would be unrepresentative of the pediatric ASD population as a whole.)- children who appear genetically syndromic (based on exam in the pediatric GI clinic)
  • taking medications
  • abnormal screening labs
  • GI diseases
  • allergy to antibiotics
  • fever or a pre-existing adverse event monitored in the study
  • known history of /C or
  • known pregnancy
  • use of probiotics in the last 60 d
  • use of oral antibiotics/anti-fungal during the previous 2 weeks
  • indwelling catheters/prosthetic devices
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Children with Autism with gastrointestinal (GI) symtpoms
  • Children with Autism without gastrointestinal (GI) symtpoms
  • Healthy Children
06

What researchers measure

Primary outcomes

  1. Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species

    Time frame: day 1

Secondary outcomes

  1. Presence of fungal species Candida tropicalis

    Time frame: day 1

  2. Presence of fungal species Candida albicans

    Time frame: day 1

  3. Presence of fungal species Saccharomyces cerevisiae

    Time frame: day 1

  4. Gastrointentinal (GI) symptoms as assessed by the GI Symptoms Severity Index

    Time frame: day 1

  5. Behavioral problems as assessed by the Aberrant Behavior Checklist (ABC)

    Time frame: day 1

  6. Behavioral problems as assessed by the Social Responsiveness Scale-2 (SRS-2)

    Time frame: day 1

  7. Oral Mycobiome Composition as assessed by sequencing of oral fungal species

    Time frame: day 1

  8. Gut inflammation as assessed by fecal calprotectin levels

    Time frame: day 1

  9. Antifungal immunity as assessed by serum dectin 1 levels

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for May 2019, 13 months after the start.

Of 57 non-industry observational studies under Autistic Disorder, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 13 months is below that.

Counting every sponsor, half of 65 studies reached it within 43 months; a quarter within 20 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2018
First posted
Apr 11, 2018
StartActual
Mar 22, 2018
Primary completionEst.
May 1, 2019
CompletionEst.
May 1, 2019
Last update
May 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03494088
Responsible party
Jane J Alookaran (Pediatric gastroenterology fellow, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Apr 11, 2018
Start date
Mar 22, 2018
Primary completion
May 1, 2019 (estimated)
Completion
May 1, 2019 (estimated)
Last update
May 14, 2018

Study contacts

Jane J Alookaran, MD
Contact
Jane.J.Alookaran@uth.tmc.edu
713-500-6098
Nicole Fatheree
Contact
Nicole.Fatheree@uth.tmc.edu
(713) 500-5669

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion